Literature DB >> 12173970

cycloSal-d4TMP pronucleotides structural variations, mechanistic insights and antiviral activity.

Chris Meiera1, Jürgen Renzea, Christian Ducho, Jan Balzarini.   

Abstract

Pronucleotides represent a promising alternative to improve the biological activity of nucleoside analogues against different viral diseases. The basic idea is to achieve nucleotide delivery into cells, bypassing limitations with intracellular formation of nucleotides from their nucleoside precursors. The cycloSal-concept is one of several pronucleotide systems reported so far. For the nucleoside analogue d4T, the cycloSal-approach improved antiviral potency. The basic idea, chemistry, different structural modifications and their effects on the antiviral potency of the cycloSal-d4TMP triesters have been discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173970     DOI: 10.2174/1568026023393183

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Chemoenzymatic syntheses and anti-HIV-1 activity of glucose-nucleoside conjugates as prodrugs.

Authors:  Tatiana Rodríguez-Pérez; Susana Fernández; Yogesh S Sanghvi; Mervi Detorio; Raymond F Schinazi; Vicente Gotor; Miguel Ferrero
Journal:  Bioconjug Chem       Date:  2010-11-15       Impact factor: 4.774

2.  The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.

Authors:  Paul L Boyer; B Christie Vu; Zandrea Ambrose; John G Julias; Svenja Warnecke; Chenzhong Liao; Chris Meier; Victor E Marquez; Stephen H Hughes
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

3.  Synthesis and anti-HIV activities of bis-(cycloSaligenyl) pronucleotides derivatives of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.

Authors:  Yousef Ahmadibeni; Rakesh Tiwari; Chelsie Swepson; Jui Pandhare; Chandravanu Dash; Gustavo F Doncel; Keykavous Parang
Journal:  Tetrahedron Lett       Date:  2010-12-15       Impact factor: 2.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.